Spark Therapeutics
NEWS
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
Here is a look at the life science companies viewed as the most innovative in the world.
The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene.
The FDA broke new ground today with a first-of-its-kind therapy for eye disease.
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
Spark Therapeutics is having a really good week in what has been a very good year.
Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
JOBS
IN THE PRESS